Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. (XLO) priced its initial public offering on Oct 22, 2021 at $16.00 per share, raising $117.6M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $426.7M. WilmerHale advised the company and Cooley advised the underwriters.

Xilio Therapeutics, Inc. is a biotechnology company developing cancer immunotherapies. Its geographically precise solutions (GPS) platform engineers cytokines and other biologics to localize their activity inside tumors, aiming to limit the systemic toxicity of immuno-oncology therapies.

Status

IPO

Ticker

XLO

Exchange

Nasdaq Global Select

Priced

Oct 22, 2021

IPO price

$16.00

Raised

$117.6M

Market cap at IPO price

$426.7M

First filed

Oct 1, 2021

Company counsel

WilmerHale

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.